Catalent (NYSE:CTLT) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a report published on Sunday. The brokerage issued a sell rating on the stock.

A number of other equities research analysts have also issued reports on the company. Stephens reaffirmed an equal weight rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. Royal Bank of Canada reaffirmed a sector perform rating and set a $63.50 price objective on shares of Catalent in a research note on Tuesday, February 20th. Barclays raised their target price on shares of Catalent from $45.00 to $47.00 and gave the stock an equal weight rating in a report on Thursday, January 25th. Finally, UBS Group restated a neutral rating and set a $63.50 price target (up previously from $58.00) on shares of Catalent in a report on Tuesday, February 6th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Catalent currently has a consensus rating of Hold and a consensus target price of $52.46.

Catalent Stock Performance

Shares of NYSE CTLT traded down $0.13 during midday trading on Friday, reaching $56.37. The company’s stock had a trading volume of 1,187,678 shares, compared to its average volume of 2,479,066. Catalent has a one year low of $31.45 and a one year high of $60.20. The company has a 50 day moving average price of $56.47 and a 200 day moving average price of $49.07. The company has a quick ratio of 1.73, a current ratio of 2.48 and a debt-to-equity ratio of 1.34.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Friday, February 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.22). Catalent had a negative return on equity of 2.43% and a negative net margin of 29.91%. The business had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the firm posted $0.62 EPS. The company’s quarterly revenue was down 10.2% compared to the same quarter last year. Equities research analysts expect that Catalent will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CTLT. Lindbrook Capital LLC raised its holdings in shares of Catalent by 79.4% during the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares in the last quarter. Gladius Capital Management LP bought a new position in Catalent during the third quarter valued at about $28,000. Exchange Traded Concepts LLC acquired a new stake in shares of Catalent in the third quarter worth about $31,000. GAMMA Investing LLC bought a new stake in shares of Catalent during the 4th quarter worth about $33,000. Finally, Cary Street Partners Investment Advisory LLC increased its holdings in shares of Catalent by 1,162.3% during the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 770 shares of the company’s stock valued at $35,000 after acquiring an additional 709 shares during the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.